MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
MWN-AI** Summary
MedMira Inc. has received Investigational Testing Authorization (ITA) from Health Canada for its innovative Multiplo® Complete Syphilis (TP/nTP) Antibody Test. This significant milestone allows the company to commence clinical trials aimed at assessing the test's efficacy for detecting both active and past syphilis cases. The trials will be conducted by REACH Nexus at the MAP Centre for Urban Health Solutions at St. Michael's Hospital, with funding sourced from the Canadian Institute of Health Research (CIHR) and Indigenous Services Canada (ISC).
The Multiplo® TP/nTP test stands out as the only commercially available diagnostic tool that can deliver results in under three minutes, from a simple finger prick sample. Unlike conventional tests, this user-friendly diagnostic device can detect treponemal (TP) and non-treponemal (nTP) antibodies in one go, addressing the pressing need for more efficient and cost-effective syphilis testing.
This approval is particularly timely, given the steep rise in syphilis cases across Canada, which reported 13,953 cases in 2022—an alarming 109% increase since 2018. The prevalence of congenital syphilis has also surged, emphasizing the necessity for rapid and accessible testing options. Dr. Sean B. Rourke of REACH Nexus highlighted the urgency of deploying such tests to underserved regions, aiming to enhance treatment connections while combatting health inequities.
MedMira, known for its quick-diagnostic technologies, believes that the Multiplo® TP/nTP test will significantly enhance the Canadian healthcare landscape, allowing healthcare providers to respond swiftly to active syphilis cases while alleviating financial burdens on the healthcare system. The collaborative effort between private sectors and public health underscores a commitment to addressing this growing public health crisis in Canada.
MWN-AI** Analysis
MedMira Inc. (TSXV:MIR) has recently announced a significant milestone with the receipt of Investigational Testing Authorization (ITA) from Health Canada for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test. This development, aimed at addressing the alarming rise in syphilis cases across Canada, positions MedMira as a potential leader in the diagnostics market for sexually transmitted infections, particularly syphilis.
The approval not only enables clinical trials to commence but also underscores a timely intervention amid surging infection rates, which have increased by 109% since 2018. The growing prevalence indicates a robust demand for effective testing solutions, offering MedMira a strategic advantage. The Multiplo® TP/nTP test, being the only combined screening and confirmation test that yields results in under three minutes, will cater to an urgent healthcare need.
Investors should consider that MedMira’s unique product, backed by partnerships with established research entities like REACH Nexus and the MAP Centre, enhances its credibility and resource accessibility. This partnership also ensures a focused approach to market launch, emphasizing collaboration with indigenous communities and underserved populations—factors that may drive future revenue growth and align with public health initiatives.
As clinical trials progress, monitoring regulatory developments and market acceptance will be critical. Investing in MedMira carries inherent risks associated with biotech firms, including dependency on successful trial outcomes and market competition. However, with the health crisis surrounding syphilis, MedMira’s innovative testing solutions present an opportunity for growth in a niche but expanding segment of the diagnostics industry.
In conclusion, the upcoming clinical trials represent a pivotal moment for MedMira; stakeholders should keep a close eye on trial results and market responses, which will be key indicators of the company’s future performance and stock viability.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trials for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP), a cutting edge device that can determine active and non-active syphilis.
The upcoming trials will be led by REACH Nexus at the MAP Centre for Urban Health Solutions at St. Michael's Hospital (Unity Health Toronto) with funding from the Canadian Institute of Health Research (CIHR) and Indigenous Services Canada (ISC).
The approval of the ITA is an important step towards getting the Multiplo® Complete Syphilis (TP/nTP) Antibody Test licensed and into the Canadian market. MedMira offers the only commercially available combined screening and confirmation test which takes less than 3 minutes (from finger prick sample to easy-to-read results) for the detection of active syphilis. The Multiplo® TP/nTP test detects both treponemal (TP) and non-treponemal (nTP) syphilis antibodies in a single diagnostic tool that targets biomarkers associated with both active and past cases of syphilis.
Unlike traditional syphilis tests, the Multiplo® Complete Syphilis (TP/nTP) Antibody Test is a user-friendly and durable diagnostic tool that addresses an urgent need for more accurate and cost-effective options to help healthcare providers to test and treat syphilis.
"Previous studies by REACH Nexus at MAP demonstrated our products high quality and flexibility. This led to the most recent testing authorization and enables MedMira to bring this much needed product closer to entering the Canadian market. Without the research team at MAP and the funding from CIHR, Canadians would not be able to benefit from this essential test. We are grateful for the support and believe in our technology and products," said Hermes Chan, CEO of MedMira. "Our Multiplo® TP/nTP is unique and there is no comparable testing solution that can provide our speed, quality and cost-effectiveness. We truly feel this is a wonderful addition to the Canadian health care sector and will enable for health care providers to act swiftly in cases of active syphilis infections while unburden the financial strain on the overall system."
This approval to begin clinical trials comes at urgent time in Canada, where rates of syphilis have skyrocketed in recent years. In 2022, there were 13,953 reported syphilis cases, with rates increasing by 109% compared to 2018, according to the latest numbers from the Public Health Agency of Canada. Congenital syphilis cases saw a 7% increase from 2021 and a 599% increase from 2018.
Amid these soaring cases, particularly in underserved and remote communities, the Multiplo® TP/nTP provides an essential testing device to help reach the undiagnosed living with syphilis.
"With the serious health crisis underway, we are doing everything we can to make sure these tests get to those who need them most, and help connect people to culturally appropriate treatment and care," said Dr. Sean B. Rourke, director of REACH and MAP scientist at St. Michael's Hospital. "This is a significant Canadian success story of how the private and public health sectors need to be working together to address health inequities."
With funding from the Canadian Institutes of Health Research (CIHR), Dr. Rourke and his team at REACH Nexus are leading efforts to address the syphilis epidemic by working collaboratively with Canadian in vitro diagnostic developers, health care providers, community stakeholders and people with lived experience, researchers, health ministries and public health to bring new POC tests to market here in Canada - while also addressing the burden of these epidemics to Canadians at the same time.
Dr. Rourke and his team at REACH Nexus have identified clinical/community sites in Alberta, Saskatchewan and Manitoba as ideal locations for this next "test, treat and connect" clinical trial and implementation science study.
About REACH Nexus at St. Michael's Hospital's MAP Centre for Urban Health Solutions
REACH Nexus is an ambitious national research group working on how to address HIV, Hepatitis C, and other sexually transmitted and blood-borne infections (STBBIs) in Canada. Their focus is on reaching the undiagnosed, implementing and scaling up new testing options, strengthening connections to care, improving access to options for prevention (PrEP and PEP) and ending stigma. We work in collaboration and partnership with people living with HIV; community-based organizations; front-line service providers; healthcare providers and decision makers; public health agencies; researchers; business leaders; industry partners, and federal, provincial and regional policymakers. Follow us on Twitter, Instagram and Facebook.
About MedMira
MedMira is a leading developer and manufacturer of Rapid Vertical Flow® diagnostics. The Company's tests provide hospitals, labs, clinics, and individuals with instant disease diagnosis, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in just three easy steps. The Company's tests are sold globally under the REVEAL®, REVEALCOVID-19®, Multiplo® and Miriad® brands. Based on its patented Rapid Vertical Flow® Technology, MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com. Follow us on Twitter and LinkedIn.
This news release contains forward?looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events, including statements regarding possible regulatory approval, product launch, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
MedMira Contact
Markus Meile
Chief Financial Officer
MedMira Inc.
ir@medmira.com
Phone 902-450-1588
REACH Nexus Contact
Andrew Russell
Senior Communications Specialist
REACH Nexus - MAP Centre for Urban Health Solutions
andrew.russell@unityhealth.to
Phone 647-237-2912
SOURCE: MedMira, Inc.
View the original press release on accesswire.com
FAQ**
How does MedMira Inc. MIR:CC plan to scale production of the Multiplo® Complete Syphilis (TP/nTP) Antibody Test to meet the increasing demand amid rising syphilis rates in Canada?
What specific outcomes does MedMira Inc. MIR:CC aim to achieve from the upcoming clinical trials led by REACH Nexus to support the adoption of the Multiplo® TP/nTP testing device?
In what ways does the Multiplo® TP/nTP test differentiate itself from traditional syphilis tests in terms of user experience and cost-effectiveness, and how does MedMira Inc. MIR:CC plan to communicate these advantages to healthcare providers?
How will the collaboration between MedMira Inc. MIR:CC and REACH Nexus impact the accessibility of syphilis testing in underserved communities across Canada?
**MWN-AI FAQ is based on asking OpenAI questions about Medmira Inc. (TSXVC: MIR:CC).
NASDAQ: MIR:CC
MIR:CC Trading
0.0% G/L:
$0.10 Last:
257,805 Volume:
$0.11 Open:
